We could not find any results for:
Make sure your spelling is correct or try broadening your search.
MONTREAL, Sept. 17, 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (โTheratechnologiesโ or the โCompanyโ) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and...
MONTREAL, Sept. 09, 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (โTheratechnologiesโ or the โCompanyโ) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and...
Q2 revenue of $22 million represents +25% growth year-over-yearPositive net income of $1 million realized with Adjusted EBITDA1 of $5.5 million Fiscal 2024 revenue guidance confirmed between $87...
MONTREAL, June 26, 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (โTheratechnologiesโ or the โCompanyโ) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and...
Poster highlights durable disease stabilization lasting beyond treatment completionResults suggest a unique, multimodal mechanism of action that differs from other cancer therapeuticsFavorable...
MONTREAL, May 09, 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (โTheratechnologiesโ or the โCompanyโ) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and...
First long-term data presentation from Parts 1 and 2 of the Phase 1 clinical trial of sudocetaxel zendusortide in solid tumors Part 3 of Phase 1 trial in advanced ovarian cancer is ongoing...
MONTREAL, April 15, 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (โTheratechnologiesโ or the โCompanyโ) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and...
MONTREAL, April 11, 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (โTheratechnologiesโ or the โCompanyโ) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and...
Q1 2024 consolidated revenue of $16.2 million Report marks third consecutive quarter of near-flat-to-positive Adjusted EBITDA1FY2024 revenue guidance confirmed between $87 and $90 million and an...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.21 | -11.170212766 | 1.88 | 1.95 | 1.59 | 32812 | 1.67867615 | CS |
4 | -0.13 | -7.22222222222 | 1.8 | 1.95 | 1.59 | 25458 | 1.69481253 | CS |
12 | -0.23 | -12.1052631579 | 1.9 | 2.28 | 1.59 | 22692 | 1.84647112 | CS |
26 | -0.1 | -5.64971751412 | 1.77 | 2.28 | 1.59 | 19528 | 1.86556886 | CS |
52 | -1.22 | -42.214532872 | 2.89 | 3.43 | 1.27 | 38267 | 1.98151707 | CS |
156 | -17.01 | -91.0599571734 | 18.68 | 22.4 | 1.22 | 34845 | 5.79340096 | CS |
260 | -21.81 | -92.8875638842 | 23.48 | 23.48 | 1.22 | 68308 | 11.53995419 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions